Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
15.31 USD | +0.13% | +2.60% | -4.11% |
Mar. 04 | Armata Pharmaceuticals Secures $35 Million Credit Agreement From Innoviva Unit | MT |
Mar. 04 | North American Morning Briefing : Stock Futures -2- | DJ |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an enterprise value anticipated at 3.84 times the sales for the current fiscal year, the company turns out to be overvalued.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.11% | 967M | C- | ||
+35.28% | 701B | C+ | ||
+26.24% | 571B | B | ||
+1.10% | 381B | C+ | ||
+20.61% | 334B | B- | ||
+16.98% | 319B | C+ | ||
+0.96% | 210B | B+ | ||
+2.31% | 210B | B- | ||
-6.52% | 201B | A+ | ||
-3.33% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock
- Equities
- Stock Innoviva, Inc. - Nasdaq
- Ratings Innoviva, Inc.